Betta Pharmaceuticals Secures NMPA Approval for MCLA‑129/Ensartinib Combination in Advanced Solid Tumors
China-based Betta Pharmaceuticals (SHE: 300558) announced that China’s National Medical Products Administration (NMPA) has approved...
Qilu Pharmaceutical & FDSTC Announce Strategic Partnership to Boost China’s Biomedical Innovation
China‑based Qilu Pharmaceutical and the Foundation for the Development of Science and Technology in China (FDSTC),...
Corxel and WuXi Forge Cardiovascular Partnership to Accelerate Drug Development
China‑based Corxel Pharmaceuticals (CORXEL) and WuXi STA, a subsidiary of WuXi AppTec (SHA: 603259), have...
Danaher Partners with Beckman to Advance Alzheimer’s Blood‑Biomarker Diagnosis
US-based science and tech services giant Danaher Corporation (NYSE: DHR) announced that its operating subsidiary,...
Johnson & Johnson Secures FDA Approval for INLEXZO, a Ground‑breaking Intravesical System for Bladder Cancer
US giant Johnson & Johnson (J&J, NYSE: JNJ) announced that the U.S. Food and Drug...
China’s 11th National Drug VBP Draft Unveils Major Pricing & Competition Reforms
The second‑draft rules for China’s 11th round of national centralized drug procurement (VBP 11th) have...
Kexing Biopharm Secures Global Rights to Humanwell PuraCap’s Nintedanib
China‑listed Kexing Biopharm Co., Ltd. (SHA: 688136) announced today a strategic commercialization agreement with Humanwell...
Novo Nordisk Launches Company‑Wide Transformation to Drive Diabetes and Obesity Growth
Danish diabetes and obesity leader Novo Nordisk A/S (NYSE: NVO) announced a sweeping organisational overhaul...
IASO Biotherapeutics & Cellbri Sign Global Cell‑Therapy Alliance
China‑based IASO Biotherapeutics and Shenzhen Cellbri Bio‑Innovation Technology Co., Ltd. announced a global strategic cooperation...
Qilu Pharmaceutical Commences Phase III Trial of QLS31905 for Advanced Pancreatic Cancer
China‑based Qilu Pharmaceutical Co., Ltd. announced that it has opened enrollment for its first‑in‑class QLS31905...
Novartis Expands Iptacopan Approval to IgA Nephropathy in China
Swiss pharmaceutical giant Novartis (NYSE: NVS) announced that its first‑in‑class oral inhibitor Iptacopan (Fabhalta) has...
Sihuan Pharma Secures IND for Dual‑Target GLP‑1/GCGR Drug P052 Injection
China‑based Sihuan Pharmaceutical Holdings Group Ltd. (HKG: 0460) announced that the Investigational New Drug (IND)...
Simcere Secures NMPA Approval for CDH17‑Targeting ADC SIM0609 in Advanced Solid Tumors
Simcere Pharmaceutical Group Limited (HKG: 2096) announced that its internally developed SIM0609, a CDH17 antibody‑drug...
DaAn Gene Secures NMPA Approval for First HIVDNA Diagnostic Kit
China‑based DaAn Gene Co., Ltd. (SHE: 002030), a research arm of Sun Yat‑sen University, announced that...
NMPA Releases Online Prescription Compliance Guidelines to Tighten Drug Retail Oversight
The National Medical Products Administration (NMPA) issued a draft of its Compliance Guidelines for Online...
Sirnaomics Secures HK$138 M Investment from Bloomage Biotech, Expanding Oncology and Aesthetic Pipelines
Sirnaomics Ltd. (HKG: 2257) announced a strategic investment agreement with Bloomage Biotech (Hong Kong) Limited, a...
RemeGen Secures China CDE Approval for Telitacicept in Sjögren’s Syndrome, First Biologic of Its Kind
China‑based pharmaceutical company RemeGen (HKG: 9995) announced that the Center for Drug Evaluation (CDE) of...
Shanghai Henlius Biotech Secures FDA IND Approval for HLX17, a Pembrolizumab Biosimilar
Shanghai Henlius Biotech, Inc. (HKG: 2696) announced that the U.S. Food and Drug Administration (FDA)...
Kintor Pharmaceutical Completes KT‑939 Tyrosinase Inhibitor Safety Trial, Highlights Cosmetic Potential
Kintor Pharmaceutical Limited (HKG: 9939) announced that it has finished enrolling 130 subjects in the...
Grand Pharma Secures CE Mark for SIR‑Spheres Y‑90, Expanding Liver‑Cancer Treatment Portfolio
Grand Pharmaceutical Group Limited (HKG: 0512) announced that SIR‑Spheres Y‑90 resin microsphere injection (brand name:...